Cancer drug tested in people with liver issues
NCT ID NCT07343960
Summary
This study aims to understand how a single dose of the cancer drug capivasertib is processed by the body in people with moderate liver problems. It will compare 20 participants with liver impairment to a control group with normal liver function. The main goal is to check if the drug behaves differently and is safe for people whose livers don't work as well.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGRialto, California, 92377, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.